NCT04111380View on ClinicalTrials.gov

Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

March 31, 2023

Study Completion Date

September 30, 2023

Conditions
Advanced Biliary Tract Cancers
Interventions
DRUG

cisplatin and nab-paclitaxel

Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.

Trial Locations (1)

450003

RECRUITING

Department of Oncology , Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou

Sponsors
All Listed Sponsors
collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

lead

Henan Provincial People's Hospital

OTHER

NCT04111380 - Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers | Biotech Hunter | Biotech Hunter